LONDON and NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) — OKYO Pharma Limited (OKYOOKYO, an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in this multi-billion-dollar market, today announces the activation of the first clinical trial site in the U.S.…Read More
OKYO Pharma Announces Activation of First Clinical Trial Site in the US for the Phase 2 Trial Evaluating OK101 for the Treatment of Dry Eye Disease OKYO Pharma NASDAQOKYO
